Join IABCN member, John Harvey, and his CONALLSTRONG team at Children’s Hospital’s Parkway Run/Walk on September 25th. Learn more by clicking HERE.
Aug16Tue
Congratulations to Irish Chamber Member company, Klasko Immigration Law Partners, on making Philadelphia Business Journal‘s “2016 Best Places to Work in Greater Philadelphia”.
Career Opportunities at Faith in the Future Foundation
Please click on the job title below for a full job description.
– Director of Principal Gifts
– Advancement Associate
– Development Intern
Aug09Tue
From Irish Echo
By Ray O’Hanlon
rohanlon@irishecho.com
Many Americans are in Ireland this month enjoying often long-planned vacations in their ancestral homeland.
Some of them are hankering to stay.
And those Americans wanting to retire to Ireland are urging changes in current financial requirements that make it impossible for many of them to meet the Irish government’s annual income rules.
Two petitions are now seeking signatures in support of the effort to lower the financial bar for residency. In response to the calls from this side of the Atlantic, and questions being asked in the Dail, mainly by Fine Gael TD Fergus O’Dowd, the Irish government has undertaken a review of the requirements starting with a “consultation phase.”
Details of the review are being made available on the website of the Irish Naturalization and Immigration Service (INIS) and “interested parties” are being asked to submit views to a dedicated email address.
Aug08Mon
|
|
|
| Craigavon, N.I., UK, – Monday 08 August 2016 Almac Group’s Diagnostics business unit today announced the publication of the second validation study of their stage II colon cancer recurrence signature ColDx in the Journal of Clinical Oncology (JCO).The publication entitled ‘Association Between Results of a Gene Expression Signature Assay and Recurrence-Free Interval in Patients With Stage II Colon Cancer in Cancer and Leukemia Group B 9581 (Alliance)’ demonstrates that the ColDx assay is a significant, independent predictor of recurrence-free interval (RFI) in stage II colon cancer therefore indicating it’s potential utility with the traditional clinical markers of risk to refine patient prognosis.
The study was performed in conjunction with the Alliance for Clinical Trials in Oncology (Alliance) comprised of investigators from renowned institutions such as Duke University, Dana-Farber Cancer Institute, University of Chicago, Brigham and Women’s Hospital and Queen’s University Belfast. |
